Human Papillomavirus - Vaccines, Then Antivirals

Introduction

Over 100 types of HPV, causing a variety of diseases, have been identified. Treatment options are limited, with no known cure currently available. However, the causal link between HPV and cervical cancer has prompted development of prophylactic vaccines, aimed at reducing the incidence, and eventually the prevalence, of this widespread disease and, by association, cervical cancer 

Scope

Provides an overview of the different strains and types of HPV infection, including detailed etiology and epidemiology 

Outlines the current treatment algorithms and options available and assesses the key unmet needs in HPV treatment 

Evaluates the various developmental treatment options, in particular the two Phase III prophylactic vaccines from Merck & GSK 

Detailed analysis and forecasts of the potential patient population and peak sales of each product, assuming a number of different scenarios 

Report Highlights

HPV is the most commonly diagnosed viral sexually transmitted disease in the US and UK, with conservative annual incidence estimates of 5.5 million in the US alone. Of these infections, it is believed that 50-75% are with high-risk HPV types, leading to approximately 500,000 new cases of cervical cancer and 232,000 deaths worldwide each year. 

Depending on which patient populations are targeted, Datamonitor believes that immunization could represent a potential market of $1-3 billion (at peak). This will be heavily influenced by optimum positioning e.g. oncogenic or STD product and official recommendation in the US. 

Datamonitor believes that beyond a prophylactic there is also sufficient need for an efficacious, simple targeted HPV therapeutic (either antiviral or biological). Based on current epidemiology and pricing benchmarks this product type could generate annual sales of $1.4 billion in the seven major markets. 

Reasons to Purchase

Analyze the commercial viability of the HPV treatment and prophylaxis market, based on estimated patient numbers 

Develop appropriate market entry and consolidation strategies through an understanding of key unmet needs 

Understand the significance of the extent of the problem of HPV infection and the associated healthcare costs 

January 2004, 80 pages 

Publisher: Datamonitor Infectious Diseases Reports 2004 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Infectious_Diseases_Reports_2004.html#a556